Banner for leaf pages 2


Also known as Tygacil

Tigecycline (INN) is a glycylcycline antibiotic developed by Francis Tally and marketed by Wyeth under the brand name Tygacil. It was given a U.S. Food and Drug Administration (FDA) fast-track approval and was approved on June 17, 2005. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus and Acinetobacter baumannii. The New Delhi metallo-β-Lactamase multidrug-resistant Enterobacteriaceae has also shown susceptibility to tigecycline.

Source: Wikipedia

Estimated Total Cost: $931.05 for an average of 7 days supply

What is it prescribed for?

Patients are most commonly prescribed tigecycline to treat pyogenic skin infection, chronic ulcer, rabies, and blastomycosis.

What drug interactions are known?

Do not take tigecycline if you are taking any of the following:

Critical Interactions

Significant Interactions

Ajax-loader Loading...